Si prevede che il mercato del trattamento dell'ematuria raggiungerà 1.103,61 milioni di dollari entro il 2028 rispetto a 932,89 milioni di dollari nel 2021; si prevede che crescerà a un CAGR del 2,4% dal 2021 al 2028.
L'ematuria è una condizione medica indicata dalla presenza di sangue nelle urine; in circostanze normali, l'urina non contiene globuli rossi. Ciò può causare problemi seri che possono causare anche calcoli renali, infezioni del tratto urinario e altre malattie ereditarie. Fattori quali l’elevata prevalenza di indicazioni associate all’ematuria, la crescente consapevolezza sulle opzioni di trattamento e il miglioramento della spesa sanitaria stanno guidando il mercato. Tuttavia, i casi non diagnosticati di indicazioni associate che ostacolano l’efficacia del trattamento ostacolano la crescita del mercato del trattamento dell’ematuria. Inoltre, si prevede che la crescente portata dei trattamenti correlati offrirà significative opportunità di crescita agli operatori del mercato del trattamento dell'ematuria per espandere la propria base di clienti, soprattutto nei paesi in via di sviluppo.Approfondimenti strategici
< p>L’Europa ha assistito a una crescita esponenziale del numero di casi di COVID-19 nel 2020. Spagna, Germania, Francia, Italia e Regno Unito sono i paesi più colpiti nella regione. È stato riportato che la proteinuria e l’ematuria hanno una prevalenza maggiore tra i pazienti con COVID-19 rispetto a quella nei pazienti con AKI. Studi retrospettivi in Cina hanno riportato che nei pazienti affetti da COVID-19 si osservano proteinuria ed ematuria e condizioni anche associate a una mortalità più elevata. Secondo il database COVID-19 della European Kidney Association (ERACODA), istituito nel marzo 2020, a circa il 25% dei pazienti sottoposti a trapianto di rene viene diagnosticata la SARS-CoV-2. Pertanto, i pazienti positivi al COVID hanno maggiori probabilità di ricevere trattamenti anche contro le malattie renali.Regioni redditizie per il mercato del trattamento dell'ematuria
< h3>Approfondimenti sul mercatoL'elevata prevalenza di indicazioni associate all'ematuria alimenta la crescita del mercato del trattamento dell'ematuria
La malattia renale cronica (IRC) è una condizione comune e pericolosa per la vita che colpisce una popolazione più ampia in tutto il mondo . Esistono vari tipi di insufficienza renale cronica, come calcoli renali, glomerulonefrite, malattia renale policistica e infezioni del tratto urinario. L’insufficienza renale cronica è una delle cause principali della prevalenza dell’ematuria. Ad esempio, secondo uno studio pubblicato nel National Center for Biotechnology Information nel maggio 2019, le infezioni del tratto urinario (UTI) sono generalmente osservate come infezioni ambulatoriali negli Stati Uniti, che si verificano soprattutto tra le donne di età compresa tra 14 e 24 anni. Inoltre, la prevalenza delle IVU tra le donne di età superiore ai 65 anni è di circa il 20% rispetto alla popolazione complessiva, che è di circa l’11%. Attualmente, il mercato globale del trattamento dell’ematuria sta guadagnando terreno in modo significativo grazie alla crescente prevalenza delle indicazioni associate. Nel Nord America, gli Stati Uniti rappresentano il mercato più grande per il trattamento dell’ematuria. La crescita di questo mercato è guidata principalmente dalla crescente prevalenza di disturbi renali cronici (CKD) e dal crescente numero di lanci di prodotti da parte dei principali attori. Ad esempio, nel 2016, i Centri per il controllo e la prevenzione delle malattie (CDC) hanno dichiarato che circa 0,7 milioni di persone sono state trattate per la malattia renale allo stadio terminale (ESRD) negli Stati Uniti. La prevalenza dell’ESRD è più che raddoppiata tra il 1990 e il 2016. Inoltre , l'aumento dell'incidenza dell'ematuria tra gli adulti, l'aumento della consapevolezza, ricerche approfondite e Si prevede inoltre che le attività di sviluppo favoriranno la prevalenza dei trattamenti per l’ematuria, che alla fine offriranno un’opportunità redditizia per la crescita del mercato. Anche l’aumento della popolazione geriatrica è uno dei principali fattori trainanti di questo mercato poiché l’invecchiamento è il principale fattore di rischio responsabile della crescente incidenza delle malattie renali. Ad esempio, secondo uno studio pubblicato dal Population Reference Bureau nel 2020, si prevede che la popolazione di 65 anni negli Stati Uniti raddoppierà entro il 2060.
Basato sul trattamento Approfondimenti
Il mercato del trattamento dell'ematuria, in base al trattamento, è segmentato in farmaci, terapie e altri. Poiché l'ematuria è associata a varie indicazioni come infezioni delle vie urinarie, calcoli renali, cancro del sangue, calcoli alla vescica e cancro alla prostata, i farmaci utilizzati per queste indicazioni possono essere utilizzati anche per il suo trattamento. Alfuzosina, ciprofloxacina, doxazosina, ibuprofene e tamsulosina sono tra i farmaci comunemente usati per il trattamento dell'ematuria. Questo è un tipo di trattamento preferito poiché i farmaci possono essere somministrati a casa e in strutture sanitarie.
Mercato del trattamento dell'ematuria, per trattamento - 2020 e 2028
Approfondimenti basati sulle indicazioni
Il mercato del trattamento dell'ematuria, basato sull'indicazione , è segmentato in calcoli renali, infezioni del tratto urinario (UTI), uretrite, cancro del sangue, calcoli alla vescica, cancro alla prostata, cistite, trauma, esercizio fisico intenso, malattia del rene policistico, endometriosi e mestruazioni. Nel 2021, è probabile che il segmento delle infezioni del tratto urinario deterrà la quota maggiore del mercato. Inoltre, si prevede che anche il mercato del trattamento dell'ematuria per l'uretrite registrerà il CAGR più rapido, pari al 3,1%, nel periodo dal 2021 al 2028.
Approfondimenti basati sul tipo
Il mercato del trattamento dell'ematuria, in base al tipo, è stato segmentato in ematuria macroscopica, ematuria microscopica, ematuria idiopatica ed ematuria del jogging. È probabile che il segmento dell'ematuria macroscopica deterrà la quota maggiore del mercato nel 2021. Tuttavia, si prevede che il segmento dell'ematuria microscopica registrerà il CAGR più elevato sul mercato durante il periodo di previsione.
Approfondimenti basati sull'utente finale
Il mercato del trattamento dell'ematuria, in base all'utente finale, è segmentato in ospedali, cliniche, centri chirurgici ambulatoriali (ASC) e altri. Nel 2021, si prevede che il segmento ospedaliero deterrà la quota maggiore del mercato. Inoltre, si prevede che anche il segmento delle cliniche vedrà una crescita della domanda al CAGR più veloce del 6,9% nel periodo dal 2021 al 2028.
Le aziende che operano nel mercato del trattamento dell'ematuria adottano la strategia di innovazioni terapeutiche per soddisfare le richieste in evoluzione dei clienti in tutto il mondo, che consente loro anche di mantenere il proprio marchio nel mercato globale.
Mercato del trattamento dell'ematuria - per Trattamento
- Farmaci
- Terapie
- Altro
Mercato del trattamento dell'ematuria: per indicazione
- Infezioni del tratto urinario
- Calcoli renali
- Uretrite
- Cancro del sangue
- Calcoli alla vescica
- Prostata Cancro
- Cistiti, traumi
- Esercizio intenso
- Rene policistico Malattia
- Endometriosi
- Mestruazioni
Mercato del trattamento dell'ematuria - per tipo
- Ematuria macroscopica
- Ematuria microscopica
- Ematuria idiopatica
- Ematuria del jogger
Mercato del trattamento dell'ematuria - per Utente finale
- Ospedali
- Cliniche
- ASC
- Altro
Mercato del trattamento dell'ematuria: per area geografica
- Nord America
- Stati Uniti
- Canada
- Messico
< li>Europa - Francia
- Germania
- Italia
- Regno Unito
- Spagna
- Resto dell'Europa
- Asia Pacifico (APAC)
- Cina
- India
- Corea del Sud
- Giappone
- Australia
- Resto dell'area APAC
- Medio Oriente e Africa (MEA)
- Sud Africa
- Arabia Saudita
- Emirati Arabi Uniti
- Resto del MEA
- America centrale e meridionale (SCAM )
- Brasile
- Argentina
- Resto di SCAM
Profili aziendali
- AstraZeneca
- Azienda Bristol-Myers Squibb
- F. HOFFMANN-LA ROCHE LTD.
- GlaxoSmithKline plc.
- Janssen Pharmaceuticals
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd
- Boehringer Ingelheim International GmbH
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Hematuria is the presence of blood in the urine. Gross or visible hematuria occurs when the urine is red or pink, indicating the presence of blood in the urine. Blood can sometimes be found in the urine but is difficult to see; this is known as microscopic hematuria since it can only be seen under a microscope. The need for hematuria treatment has increased as the incidence of chronic renal disease and urinary tract infections has increased. Many tests, such as screening for sugar (diabetes), germs (infection), and blood, are performed on a regular basis. Blood can be detected with a chemical strip (also known as a dipstick) or under a microscope.
Key factors that are driving the growth of this market are high prevalence of hematuria-associated indications and increasing awareness about treatment options and improving healthcare expenditure are expected to boost the market growth for the hematuria treatments over the years.
The CAGR value of the hematuria treatments market during the forecasted period of 2021-2028 is 2.4%.
The drugs segment held the largest share of the market in the global hematuria treatments market and held the largest market share of 56.99% in 2020.
The urinary tract infections segment dominated the global hematuria treatments market and accounted for the largest market share of 17.31% in 2020.
The macroscopic hematuria segment dominated the global hematuria treatments market and held the largest market share of 48.04% in 2020.
The hospitals segment dominated the global hematuria treatments market and held the largest market share of 36.52% in 2020.
The hematuria treatments market majorly consists of the players such AstraZeneca, Bristol-Myers Squibb Company, F. HOFFMANN-LA ROCHE LTD., GlaxoSmithKline plc., Janssen Pharmaceuticals, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd, Boehringer Ingelheim International GmbH among others.
The List of Companies - Hematuria Treatment Market
- AstraZeneca
- Bristol-Myers Squibb Company
- F. HOFFMANN-LA ROCHE LTD.
- GlaxoSmithKline plc.
- Janssen Pharmaceuticals
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd
- Boehringer Ingelheim International GmbH
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Oct 2021
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Oct 2021
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Oct 2021
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Oct 2021
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Oct 2021
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Oct 2021
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Oct 2021
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Oct 2021
Hyperpigmentation Disorder Treatment Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Cosmeceutical, Light or Laser Therapy, Microdermabrasion, Chemical Peels, Cryotherapy, and Others), Condition (Melasma, Solar Lentigines, Post-Inflammatory Hyperpigmentation, and Others), End User (Hospitals, Dermatology Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)